The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves' disease.

ABSTRACT:

Background

The bioassay of thyroid-stimulating immunoglobulin was reported to have a similar performance to the commonly used thyroid-stimulating hormone binding inhibition assay, also known as thyroid receptor antibody assay. The normal reference range of thyroid receptor antibody levels indicates the withdrawal of anti-thyroid drugs in the recent clinical guidelines.

Methods

A prospective, longitudinal observational study was conducted to evaluate the prognostic value of thyroid-stimulating immunoglobulin in patients with Graves' disease.

Results

A total of 77 patients with Graves' disease treated with anti-thyroid drugs were in a continuous follow-up until 1 year after anti-thyroid drugs discontinuation. Commercial kits of thyroid-stimulating immunoglobulin and M22

SUBMITTER: Zhou Y 

PROVIDER: S-EPMC8481717 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature